Actinogen Medical Limited is an Australia-based biotechnology company. The Company is focused on developing therapy for neurological diseases associated with dysregulated brain cortisol. Its lead compound, Xanamem, is a therapy for Alzheimer’s disease, fragile x syndrome, major depressive disorder and other neurological diseases. It is designed to block the production of cortisol the stress hormone in the brain. Xanamem is an inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the central nervous system. It is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in neuropsychiatric diseases. The Company focuses on developing Phase II clinical trial evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer.